These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34454589)

  • 1. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
    Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
    Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
    Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
    BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
    Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
    Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
    Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
    Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and bioinformatics analysis of the relationship between LAMA3 DNA methylation expression and platinum resistance and prognosis in epithelial ovarian cancer].
    Chen CX; Zhang YL; Huang YZ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2024 Jun; 59(6):454-464. PubMed ID: 38951081
    [No Abstract]   [Full Text] [Related]  

  • 9. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
    Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
    Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer.
    Watanabe Y; Ueda H; Etoh T; Koike E; Fujinami N; Mitsuhashi A; Hoshiai H
    Anticancer Res; 2007; 27(3B):1449-52. PubMed ID: 17595760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide DNA methylation profiling integrated with gene expression profiling identifies
    Rani L; Mathur N; Gupta R; Gogia A; Kaur G; Dhanjal JK; Sundar D; Kumar L; Sharma A
    Clin Epigenetics; 2017; 9():57. PubMed ID: 28572861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
    Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
    Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
    Qiu PY; Deng XH; Li L
    Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TR3 modulates platinum resistance in ovarian cancer.
    Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
    Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
    Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
    Gyparaki MT; Papavassiliou AG
    Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
    [No Abstract]   [Full Text] [Related]  

  • 20. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.